RxDoctor Payments Data

Shubha Shetty, MD

Family Medicine · Missouri City, TXNPI 1760645295

Payments from drug & device makers

$3,251in general payments, 2019–2025

Across 84 payments — averaging $38.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$826
  • Novo Nordisk$676
  • Amgen$467
  • Lilly USA, LLC$339
  • Abbott$164
  • AbbVie$125
  • plus $653 from 13 others

What the payments were for

  • Food & beverage$3,23199%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,251 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$47,362
Medicare patients
105
Services billed
645

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide86$115,739
MounjaroTirzepatide34$48,313
FarxigaDapagliflozin Propanediol23$27,360
JanuviaSitagliptin Phosphate15$22,895
EliquisApixaban18$20,414
MyrbetriqMirabegron15$13,762
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$7,159
Lantus SolostarInsulin Glargine,hum.Rec.Anlog30$4,097
Dexlansoprazole DrDexlansoprazole13$3,202
Calcipotriene12$2,149
Atorvastatin Calcium254$2,092
Rosuvastatin Calcium132$2,047
Wixela InhubFluticasone Propion/Salmeterol11$1,815
Gabapentin95$1,815
Levothyroxine Sodium144$1,645

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$676$115,73986 claims
Lilly USA, LLCMounjaro$339$48,31334 claims
AstraZenecaFarxiga$826$27,36023 claims
AbbVieSynthroid$125$1,33726 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Missouri City

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →